Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Autoantibodies to different subtypes of the voltage-gated calcium channel (VGCC) have been described in two very different neurological syndromes, the Lambert-Eaton myasthenic syndrome (LEMS) and amyotrophic lateral sclerosis (ALS). In this chapter we discuss the evidence supporting the role of anti-P/Q-type VGCC autoantibodies in the pathogenesis of LEMS but challenging the role of any VGCC autoantibodies in ALS. © 2014 Elsevier B.V. All rights reserved.

Original publication




Journal article

Publication Date



629 - 636